Role and Function of GSK-3 in the Regulation of Immunity
A special issue of Biology (ISSN 2079-7737). This special issue belongs to the section "Medical Biology".
Deadline for manuscript submissions: closed (28 December 2021) | Viewed by 3879
Special Issue Editors
Interests: GSK-3; T cells; immunotherapy; immune checkpoint blockade; signaling; cancer
Special Issue Information
Dear Colleagues,
Glycogen Synthase kinase (GSK)-3 is a multifunctional serine/threonine kinase implicated in several disease states and key cellular processes, including Wnt, insulin and Hedgehog signalling. There are two paralogs of GSK-3 and together they are known to phosphorylate over 100 substrates yet much of the mechanism/s behind GSK-3 regulation remains to be fully elucidated.
GSK-3 has been found to play a key role in diabetes, Alzheimer disease, inflammation and cancer, and there are studies in which the inactivation of GSK-3 can have a positive effect in these diseases. A classic inhibitor of GSK-3; lithium Chloride, has been used for decades as a mood stabiliser to treat bipolar disorder, however further inhibitors of GSK-3 have struggled to pass clinical trials due to issues around toxicity. This may be due to inhibitor specificity or more likely the many other pathways GSK-3 may be affecting alongside that desired. Specific targeting of GSK-3 whether it be in specific cells/ tissue or one of the paralogs of GSK-3 will not only advance our knowledge in this area but may lead to the development of new and/or improved immunotherapies.
This Special Issue welcomes the submission of original research and review manuscripts on all aspects of GSK-3 function in the immune response, covering mechanisms by which GSK-3 may control disease, roles for the two paralogs and the possible targeting and application of GSK-3 in immunotherapies, to bring together current ideas and opinions about this extraordinary kinase, discuss what remains to be discovered and stimulate the emergence of new ideas to develop the advancement/generation of new therapeutic approaches.
Dr. Alison Taylor
Dr. Anke Brüning-Richardson
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- GSK-3
- T cells
- Immunotherapy
- immune checkpoint blockade
- signaling
- cancer
